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a b s t r a c t
IFI44 is an interferon-alfa inducible protein, and is associated with infection of several viruses. However,
IFI44 elicits minimal antiviral effects on these viruses, and its exact role is still unknown. Here we show
that IFI44 inhibits HIV-1 replication in vitro. Through depletion of endogenous IFI44 or overexpression of
IFI44 we conﬁrm that IFI44 suppresses HIV-1 LTR promoter activity and affects viral transcription.
Furthermore, we ﬁnd that IFI44 localizes to nuclei and binds to the HIV-1 LTR promoter in HIV-1 infected
cells. Removing suppression of HIV-1 transcription beneﬁts reactivation of HIV-1 proviruses for purging
latent reservoirs. We demonstrate that depletion of endogenous IFI44 in J-LAT cells induces reactivation
of latent HIV-1. Based on these results, we propose a model in which IFI44 is recruited to the HIV-1 LTR,
which may suppress viral transcription and prevent reactivation of latent HIV-1. Our study suggests a
previously unrecognized anti-HIV phenomenon for interferon-stimulated proteins.
& 2015 Elsevier Inc. All rights reserved.
Introduction
Type I interferon, IFN-α⧸β, binds to the interferon receptor and
potently induces antiviral responses by initiating a signaling
cascade that leads to the expression of thousands of interferon-
stimulated genes (ISGs) and a generalized antiviral state. IFN-α can
block HIV-1 replication at multiple steps including viral entry,
reverse transcription, viral protein synthesis and processing, and
viral assembly and release (Baca-Regen et al., 1994; Coccia et al.,
1994; Fernie et al., 1991; Gendelman et al., 1990a, 1990b; Hansen
et al., 1992; Barr et al., 2008). Several anti-HIV ISGs have recently
been identiﬁed, including tetherin, TRIM5 alpha, APOBEC3 (apoli-
poprotein B mRNA-editing, enzyme-catalytic, polypeptide-like 3),
and SAMHD1 (SAM domain and HD domain-containing protein 1)
(Malim and Bieniasz, 2012; Strebel et al., 2009; Harris et al., 2012).
However, discovery of these ISGs is just tip of the iceberg, other
ISGs with potential to antagonize HIV-1 intracellular replication
are pending for identiﬁcation and further investigation.
IFI44 expression is inducible by IFN-α⧸β but not by IFN-γ
(Kitamura et al., 1994), and is associated with infections of several
viruses. IFI44 was initially found as a hepatitis C virus (HCV)
associated microtubular aggregate protein isolated from the hepa-
tocytes of HCV-infected chimpanzees (Honda et al., 1990). IFI44 is
differentially expressed in rhinovirus (RV) infected primary bron-
chial epithelial cells derived from humans with asthma vs. normal
subjects (Bochkov et al., 2010). Early stage human papillomavirus
(HPV) infections also induce IFI44 expression in a human kerati-
nocyte line (Kaczkowski et al., 2012), seemingly through the
expression of HPV E7 oncoprotein (Boccardo et al., 2010). How-
ever, HIV-1 infection seems to down-regulate expression of a set of
ISGs in primary macrophages, including IFI44 (Wie et al., 2013).
Although it is suggested that IFI44 may mediate the antiviral
activity of type I interferon, there is no experimental data to
support it, for example, in HCV infections (Balan et al., 2006; Liu
et al., 2007). Recently, a study of IFN-β induced the inhibition of
bunyamwera orthobunyavirus (BUNV) replication, demonstrating
that overexpression of IFI44 leads to an approximately 10-fold
reduction of BUNV replication in HEK293 cells (Carlton-Smith and
Elliott, 2012). However, the exact antiviral mechanism of IFI44
remains elusive. One possible link is that IFI44 may induce an anti-
proliferative state in certain cell types in vitro (Hallen et al., 2007),
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but still lacks direct evidence for how exactly it contributes to
IFI44's antiviral activity. It remains possible that IFI44 may exploit
alternative strategies to restrict viral replication. Our earlier
comprehensive siRNA screens identiﬁed IFI44 as a leading candi-
date of HIV-1 restriction factor (Zhu et al., 2014). We would like to
further explore whether IFI44, as a general antiviral ISG, may also
possess anti-HIV activity and its potential molecular mechanism.
Results
IFI44 depletion enhances HIV-1 infection
We ﬁrst measured IFI44 expression in MAGI-HeLa, Jurkat,
CD4þ and CD8þ T cells. Even without IFN treatment, IFI44
maintained a basal level of expression in these cells, although it
seemed that IFI44 had higher expression in T cells compared to
epithelial cells (Fig. S1). Consistent with previous studies, IFI44
expression was highly inducible upon IFN-α stimulation, but to a
lesser degree with IFN-γ (Fig. S1). We were able to efﬁciently
deplete basal endogenous expression of IFI44 using two sequence-
unique siRNAs (Fig. 1A). We infected IFI44-depleted MAGI-HeLa
cells with HIV-1 IIIB and measured the intracellular HIV-1 capsid
protein p24 expression by immunostaining using an anti-p24
antibody. We set up a ﬁxed threshold of p24 signal from the FITC
channel, and any cell with the p24 signal above the threshold was
counted as an HIV-infected cell. HIV-1 infection rate was calcu-
lated by dividing the p24-expressing cells by the total cells
(staining of nuclei with Hoechst). IFI44 depletion effectively
increased the HIV-1 infection rate in MAGI-HeLa cells with or
without IFN-α stimulation (Fig. 1B). We also tested two VSV-G
pseudo-typed viruses (HIV-NL4-3-GFP [ΔEnv], MLV-GFP [ΔEnv])
as well as lentiviral vectors harboring different promoters (LTR-
GFP, CMV-ZsGreen [ZSG]), which were used in previous studies
(Zhu et al., 2014). A threshold of GFP signal was decided to
determine GFP-positive, virus-infected cells. GFP-positive cells
were counted and normalized by total cell numbers to calculate
viral infection rate for individual virus or viral vector. We noticed
that IFI44 depletion did not affect MLV-GFP infection rate (Fig. 1C).
Furthermore, IFI44 depletion increased LTR-driven GFP expression
but not CMV promoter (Fig. 1D). These results indicate that IFI44
may target HIV-1 LTR promoter activity speciﬁcally. We further
conﬁrmed the anti-HIV effects of IFI44 in Jurkat cells. We gener-
ated pAPM lentiviral vectors expressing two sequence-unique
IFI44 shRNAs, and transduced them individually to Jurkat cells.
Both IFI44 shRNAs were able to deplete basal expression of IFI44 in
Jurkat cells (Fig. 1E), while enhancing infection rate of VSV-G
pseudo-typed HIV-NL4-3-GFP [ΔEnv] in these cells, measured by
ﬂow cytometry (Fig. 1F).
IFI44 expression reduces HIV-1 LTR activity
We also used a gain-of-function approach to test the anti-HIV
activity of IFI44. We cloned HA-tagged IFI44 cDNA (HA-IFI44) into
the pQCXIP retroviral vector. It was transduced to MAGI-HeLa,
HEK293, and JLTRG cells. Cells were also transduced in parallel with
empty pQCXIP vector as a negative control. Stable cells were selected
by incubating with puromycin. HA-IFI44 expression was conﬁrmed
by either western blot to measure protein level (Fig. 2A and C) or
reverse transcription-coupled qPCR to measure mRNA level (Fig. 2E).
MAGI-HeLa cells expressing IFI44 signiﬁcantly decreased HIV-IIIB
infection rate with the presence or absence of IFN-α (Fig. 2B). To rule
out the possibility that this could be an artiﬁcial effect due to
overexpression of IFI44, we measured the EBV lytic replication
induced by 12-O-tetradecanoylphorbol-13-acetate (TPA) and sodium
butyrate (SB) in AGS/BX cells expressing IFI44 (Fig. S2). The result
demonstrated no obvious suppression of EBV replication, which
indicates that IFI44-mediated suppression of HIV-1 replication is
speciﬁc. We further performed an LTR-luciferase assay in HEK293
cells expressing IFI44. Consistent with our LTR-GFP expression results
in IFI44-depleted cells (Fig. 1D), we found that IFI44 expression
signiﬁcantly lowered the LTR-driven luciferase expression (Fig. 2D).
We also tested IFI44 anti-LTR effects in JLTRG cells, which are Jurkat
cells with a stably integrated LTR-GFP construct but no TAT expres-
sion (Ochsenbauer-Jambor et al., 2006). We transiently transfected a
pcDNA vector expressing FLAG-tagged TAT (FLAG-TAT) into JLTRG
cells expressing IFI44, and measured GFP-positive cells by ﬂow
cytometry. Similar to the LTR-luciferase results, IFI44 expression
reduced the TAT-mediated LTR-GFP expression (Fig. 2F).
IFI44 nuclear localization and association with LTR promoter
Our genetic studies indicate that IFI44 may speciﬁcally sup-
press HIV-1 LTR promoter activity (Figs. 1D, 2D). However, earlier
studies suggest that IFI44 may be a cytoplasmic protein (Hallen
et al., 2007). Using a HEK293 cell line stably expressing IFI44, we
conﬁrmed that the majority of IFI44 was in the cytoplasm, but
IFI44 localized to nuclei upon HIV-1 infection using VSV-G
pseudo-typed HIV-1 NL4-3-GFP [ΔEnv] virus (Fig. 3A). This result
is supported by the immunostaining of HEK293 cells showing
increased nuclear localization of IFI44 upon HIV-1 infection (Fig.
S3A and B). We further conﬁrmed that nuclear IFI44 bound
speciﬁcally to certain regions of HIV-1 LTR promoter by conducting
a chromatin immuno-precipitation (ChIP) coupled to detection by
semi-quantitative PCR (ChIP-PCR) experiment. IFI44 was strongly
associated with the nuc-0, nuc-1, and nucleosome-free region
(PPR) of the HIV-1 LTR, but not the nuc-2 region (Figs. 3B, S3C).
Considering that viral transcription is initiated within the PPR
between nuc-0 and nuc-1 (Verdin et al., 1993), we postulate that
the presence of IFI44 at the HIV-1 LTR may interfere with viral
transcription initiation. However, GST-TAT pull-down assays
demonstrated that IFI44 recruitment to HIV-1 LTR might not be
mediated through interaction with HIV-1 TAT transactivator,
indicating that IFI44 may be recruited to the HIV-1 LTR through
an unidentiﬁed mechanism (Fig. S3D and E).
IFI44 depletion reverses HIV-1 latency
Since IFI44 signiﬁcantly suppresses HIV-1 transcription, we
postulate that it may play a role in facilitating HIV-1 latency while
preventing viral reactivation. We transduced two IFI44 shRNAs
into several J-LAT cells, which are Jurkat cells harboring latently
infected GFP-fused HIV proviruses (Jordan et al., 2003). To analyze
the efﬁciency of HIV-1 reactivation, the population of GFP-
expressing cells, indicating restoration of viral transcription, were
sorted and analyzed by ﬂow cytometry. We ﬁrst conﬁrmed the
IFI44 shRNA knockdown efﬁciency by measuring basal IFI44
mRNA level in J-LAT A2 cells harboring a mini HIV genome (LTR–
TAT–GFP) (Fig. 4A). Interestingly, depletion of IFI44 reversed HIV-1
latency up to 2–3 folds in J-LAT A2 cells, which exerted the effect
spontaneously without treatment of HIV-1 latency-reversing
agents (LRAs) (Fig. 4B and C). We also evaluated the effect of
IFI44 depletion in another two J-LAT cell lines, 6.3 and 9.2, which
harbor Env-deleted full-length HIV-1 NL4-3-GFP proviruses. We
did not see any obvious effect on HIV-1 reactivation by depleting
endogenous IFI44, but shRNA-mediated IFI44 knock down seemed
to mildly beneﬁt HIV-1 reactivation once cells were treated with
Prostratin, a potent HIV-1 LRA, which activates the NF-κB pathway
(Williams et al., 2004) (Fig. S4).
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Discussion
Although it is clear that type I IFN induces potent cellular
defense against viral infection mediated by up-regulation of ISGs,
the exact function for most of them is unknown and demands
further characterization. Only until recently ISGs have been
scrutinized individually for determining their antiviral activity
against a set of various virus families (Schoggins et al., 2011,
2014). In this work, we describe that one of the ISGs, IFI44, may
reduce HIV-1 replication possibly through affecting viral
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Fig. 1. IFI44 depletion by RNAi increases HIV-1 infection. (A) MAGI-HeLa was transfected with sequence-unique IFI44 siRNA, siIFI44-1 or siIFI44-2, or non-targeting control
siRNA (siNT). 72 h post-transfection, total RNAwas extracted for reverse transcription and quantitative real-time PCR to measure the IFI44 mRNA level. Data were normalized
to the siNT-treated cells. (B) MAGI-HeLa was transfected with siIFI44-1, siIFI44-2, or non-targeting siNT. 48 h post-transfection, cells were treated with IFN-α, or mock treated
for 24 h. Cells were then infected with HIV-IIIB wild-type viruses for 48 h, and stained with anti-HIV-1 p24 CA antibody (anti-CA) and a FITC anti-mouse secondary antibody.
Nuclei were stained using Hoechst. The percentage of infected cells was measured and normalized to the siNT-treated cells. (C, D) MAGI-HeLa was transfected with siIFI44-1,
siIFI44-2, or siNT. 72 h post-transfection, cells were infected with VSV-G pseudo-typed (C) HIV-NL4-3-GFP [ΔEnv] or MLV-GFP virus [ΔEnv], or (D) LTR-GFP or CMV-ZSG
lentivirus for 48 h. Cells were stained with Hoechst and the percentage of GFP-positive cells was measured and normalized to the siNT-treated cells. (E) Sequence-unique
IFI44 shRNA, shIFI44-1, shIFI44-2, or control ﬁreﬂy luciferase shRNA (shFLuc) in pAPM vector was transduced in Jurkat T cells. Cells were subjected to RNA extraction, reverse
transcription, and quantitative real-time PCR for measuring the IFI44 mRNA level. Data were normalized to the shFLuc-transduced cells. (F) Jurkat T cells stably expressing
shIFI44-1, shIFI44-2, or shFLuc were infected with VSV-G pseudo-typed HIV-NL4-3-GFP [ΔEnv] viruses for 48 h. Cells were assessed using ﬂow cytometry and the percentage
of GFP-positive cells was calculated and normalized to the shFLuc-transduced cells. All results were presented as mean7s.d. (n¼3); *Po0.05 from t-test.
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transcription. We demonstrate that IFI44 may enter nuclei and
bind with the HIV-1 LTR promoter to produce an inhibitory effect
on HIV-1 transcription. Furthermore, our results using HIV-1
latently infected Jurkat cells suggest that IFI44 may play a role in
facilitating HIV-1 latency while preventing reactivation due to its
suppressive activity toward viral transcription.
In most of our studies, we measured the infection rate by
deciding a threshold of the signal indicating HIV-1 infection, such
as intracellular p24 or virus-fused GFP expression, and then
counting the percentage of HIV-infected cell. We routinely use
this as an indicator of viral intracellular replication, which pro-
vides a great dynamic range, to measure results of our siRNA
screens and further genetic validations of host genes (Zhu et al.,
2014; Brass et al., 2008; Zhu et al., 2012). We show that either
basal or IFN-α induced expression of IFI44 contributes to restric-
tion of HIV-1 intracellular replication (Fig. 1). This is not unusual,
since studies of other ISGs demonstrate that even basal expression
of ISGs still possess certain antiviral activity. For example, the high
basal expression of an ISG, TRIM5α, in peripheral blood mono-
nuclear cells (PBMCs) dramatically restricts mucosal transmission
of simian immunodeﬁciency virus (SIV) more efﬁciently than
when induced with type I IFN (Aamer et al., 2014). Certain host
genes, including recently discovered tyrosine kinase nonreceptor 1
(TNK1), are required for maintenance of basal ISG expression (Ooi
et al., 2014). Although IFI44 is implicated to play a role in
regulating the replication of various viruses, it was never reported
previously as a HIV-1 restriction factor. In addition, our ﬁndings
seem to align with an earlier study, which shows that IFI44
expression is down-regulated in IFN-treated primary macrophages
upon HIV-1 infection (Wie et al., 2013). Above all, we conclude
that IFI44 imposes an inhibitory effect on HIV-1 replication while
evolutionarily HIV-1 may have developed a strategy to suppress
the antiviral activity of IFI44 in order to beneﬁt its replication,
which is worthy of further investigation. However, we did not
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notice that HIV-1 infection led to IFI44 degradation (data not
shown), so it is unlikely that HIV-1 proteins, such as Vif, Vpu, Vpr,
and Vpx, may mask antiviral activity of IFI44, considering that
these accessory proteins can associate with certain antiviral
proteins and induce their proteasome-dependent degradation
(Yu et al., 2003; Douglas et al., 2009; Romani and Cohen, 2012;
Ahn et al., 2012).
Our IFI44 localization experiments conﬁrm that the majority of
exogenously expressed IFI44 is retained within the cytoplasm,
which is consistent with an earlier study that describes IFI44 as a
cytoplasmic protein that may associate with microtubules (Hallen
et al., 2007). However, the surprising discovery from our study is
that IFI44 partially diffuses into nuclei of HEK293 cells upon HIV-1
infection (Figs. 3A, S3A and B). Hallen et al. (2007) claimed that
endogenous IFI44 was detected in the nuclei of nonstimulated
human melanoma cell lines ME15 and D10 cells by immunostain-
ing using a custom-made anti-IFI44 antibody. They failed to
conﬁrm the presence of IFI44 in nuclear fraction using the same
antibody; therefore, IFI44 nuclear localization is inconclusive
based on their studies. Using a HA epitope fused IFI44 cDNA, we
clearly show that IFI44 partially localizes within nuclei, which is
further enhanced upon HIV-1 infection. More importantly, we
demonstrate that IFI44 in nuclear fraction is strongly associated
with the HIV-1 LTR promoter region by ChIP-PCR assays (Fig. 3B).
This is critical evidence that may explain IFI44's inhibitory effect
on HIV-1 LTR activity and viral transcription (Figs. 1D, 2D). We rule
out the possibility that increased IFI44 localization in nuclei or
IFI44 recruitment to LTR upon HIV-1 infection may be mediated by
interaction with HIV-1 TAT protein, which encodes a nuclear
localization sequence (NLS) (Efthymiadis et al., 1998) and associ-
ates with HIV-1 LTR through TAR RNA (Selby and Peterlin, 1990;
Dingwall et al., 1989), since our GST-TAT pull-down and FLAG-TAT
co-immunoprecipitation assays failed to detect that TAT interacted
with IFI44 (Fig. S3D and E). We will continue to investigate exactly
how HIV-1 infection facilitates IFI44 nuclear localization and by
which means IFI44 is recruited to the HIV-1 LTR promoter to
modulate its activity.
We also conﬁrm that the presence of IFI44 may facilitate HIV-1
latency and prevent its reactivation, very likely through suppres-
sion of viral transcription. We tested cells harboring the mini-HIV
genome (J-LAT A2) (Fig. 4) and two J-LAT clones harboring Env-
deleted full-length HIV genome (6.3, 9.2) (Fig. S4). Our earlier
studies suggest that the mini HIV-1 in J-LAT A2 is more susceptible
to reactivation than the full-length HIV-1 in J-LAT clones, probably
because sole induction of transcriptional initiation is not sufﬁcient
to potently reverse latency for full-length HIV-1. Latent stage of
full-length HIV-1 may be subjected to other regulatory machi-
neries. Since our data show that IFI44 is recruited to the LTR
(Fig. 3B) and suppresses LTR promoter activity (Figs. 1D, 2D), we
expect that IFI44 may inhibit transcriptional initiation. Depletion
of IFI44 is able to remove certain HIV transcriptional inhibition,
which is more sufﬁcient to reverse the mini HIV genome (J-LAT
A2) than the full-length HIV (J-LAT 6.3 and 9.2). Type I IFN may not
only restrict ongoing viral replication but also prevent the reacti-
vation of HIV provirus. Thus, IFN-mediated inhibitory effects
contribute substantially to establishment and/or maintenance of
HIV-1 latency and persistent infection. An earlier study demon-
strates that IFN-α suppresses HIV-1 gene expression in certain
chronically infected cell lines (Poli et al., 1989). Later, it is reported
that by transferring human CD4þ T cells expressing IFN-β into a
mouse model of persistent HIV infection results in reduced
infection and a restoration of the CD4þ T cell population
(Vieillard et al., 1999). Recently, a study in a small group of AIDS
patients suggests that IFN-α therapy may facilitate the reduction
of HIV-1 proviral DNA level and clearance of HIV-1 latency
reservoir in some individuals with well-controlled HIV-1 infection
once antiretroviral therapy is interrupted (Azzoni et al., 2013;
McNamara and Collins, 2012). Furthermore, the antiretroviral
capacity of IFN-α in vivo correlates with the increased expression
of certain host restriction factors (Pillai et al., 2012). These results
demonstrate that type I IFN treatment controls persistent HIV-1
infection in AIDS patients although the exact mechanism is still
unclear. We postulate that IFI44 may be one of the mediators of
the IFN-α antiviral effect, which partially suppresses latent HIV-1
from reactivation, and its role in the IFN-α regulation of HIV-1
persistence in vivo shall be further investigated in future.
In summary, we identify an IFN-α inducible protein, IFI44, as a
HIV-1 restriction factor. HIV-1 infection may lead to IFI44 localiza-
tion to nuclei and recruitment to the HIV-1 LTR promoter region,
which could be a prerequisite for the suppression of HIV-1
transcription to promote its latency. HIV-1 latent reservoirs remain
the major obstacle for HIV-1 elimination. Understanding host
restrictive machineries facilitating HIV-1 latency, especially those
induced by type I IFN, including IFI44, will be crucial for identify-
ing new gene targets for purging latent HIV-1 reservoirs as a cure
strategy.
Materials and methods
Cell lines
The following cells were generously provided by the NIH AIDS
reagent repository: MAGI-HeLa, Jurkat Clone E6-1 (Catalog #177,
(Weiss et al., 1984)), J-LAT A2 (Cat. #9854), 6.3 (Cat. #9846), 9.2
(Cat. #9848). MAGI-HeLa and HEK293 cells were cultured in
Dulbecco's modiﬁed eagle medium (DMEM, Life Technologies)
supplemented with 10% fetal bovine serum (FBS, Life Technolo-
gies); all Jurkat-derived cells were cultured in RPMI 1640 medium
(Life Technologies) supplemented with 10% FBS. For interferon
treatment, recombinant human interferon alpha (IFN-α,
2.5105 units/ml) or human interferon gamma (IFN-γ, 2.5 mg/
ml) (PBL Assay Science) was added to the medium and incubated
for 24 h. AGS/BX cells were cultured in Ham's F-12K (Life Tech-
nologies) nutrient mixture supplemented with 10% FBS.
Viruses
The HIV-1 IIIB wild-type strain (Brass et al., 2008) was obtained
from the NIH AIDS Reagent Repository. VSV-G pseudotyped
viruses were created by co-transfecting HEK293T cells with pCG-
VSV-G and the following viral constructs: HIV-1 NL4-3-Luc (ΔEnv),
HIV-1 NL4-3-GFP (ΔEnv), HIV-1 LTR-GFP (LTR-GFP), CMV-ZSG
(pPHAGE-CMV-ZSG), and MLV-GFP (Brass et al., 2008; Valle-
Casuso et al., 2012). pAPM pseudo-typed lentiviruses were created
by co-transfecting HEK293T cells with psPAX2 and pMD2.G
(Addgene #12260, #12259) with the subcloned pAPM shRNA
constructs.
Antibodies
An anti-HIV-1 p24 mouse monoclonal antibody, mab-183, was
obtained from the NIH AIDS Reagent Repository. Mouse (puriﬁed
Clone HA.11, Covance) and rabbit (Bethyl Laboratories Inc.) HA
antibodies were used for immunoblotting and immunostaining of
HA-IFI44. A Texas Red conjugated goat anti-rabbit (Rockland) and
a goat anti-mouse Alex-Fluor 488 (Life Technologies) secondary
antibody were used for immunostaining. GAPDH, E-cadherin, and
JMJD1A antibodies (Santa Cruz Biotechnology) were used for
immunoblotting. A goat anti-mouse or anti-rabbit IgG-HRP (Santa
Cruz Biotechnology) was used as secondary for immunoblotting.
The rabbit HA antibody and a Rabbit IgG isotype control (Southern
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Biotech) were used for chromatin immunoprecipitation and co-
immunoprecipitation assays.
Plasmids
pQCXIP-HA-IFI44 was constructed by subcloning IFI44 with an
N-terminal HA peptide into the pQCXIP retroviral vector (Clon-
tech) using AgeI and PacI sites. Pseudotyped viruses were
packaged using pCG-VSV-G and pCG-Gag-Pol vectors. pQCXIP-
FLAG-TAT was constructed by subcloning TAT with C-terminal
FLAG peptide into the pQCXIP vector using NotI and BamHI sites
(Zhu et al., 2012). pCDNA-FLAG-TAT was obtained from the NIH
AIDS Repository. pAPM shRNA vectors were constructed by sub-
cloning shRNA species into pAPM vector using EcorI and
XhoI sites.
RNAi reagents
siRNAs were transfected at 50 nM ﬁnal concentration using
Oligofectamine transfection reagent (Life Technologies). The con-
trol siRNA contains a pool of Silencer Negative siRNAs (Nos. 1–4,
AM4611, AM4613, AM4615 and AM4641, Life Technologies). IFI44
siRNAs: si1, 50- UAU ACU UCU CAG AUA UCC C -30; si2, 50- UCU AUC
ACG AAU GUU ACC G -30 (Life Technologies). shRNAs were
subcloned into the pAPM shRNA expression vector. pAPM is a
microRNA (mir30)-based shRNA lentiviral vector where both the
puromycin N-acetyltransferase cDNA and the shRNA are expressed
via the spleen focus-forming virus (SFFV) promoter (Pertel et al.,
2011). Production of pAPM shRNA lentivirus has been described
previously (Bernasconi et al., 2010). The control shRNA targets
ﬁreﬂy luciferase version 2 (FLuc, 50- TAC AAA CGC TCT CAT CGA
CAA G -30). IFI44 shRNAs: sh1 (50- TCT ATC ACG AAT GTT ACC GTT C
-30); sh2 (50- TAT ACT TCT CAG ATA TCC CAG T -30).
Immunostaining
MAGI-HeLa cells (approximately 3,000 per well) were reverse
transfected with siRNA in 96-well plates. At 72 h post-transfection,
cells were infected with HIV-IIIB in 150 ml fresh DMEMmedium. At
48 h post-infection, cells were ﬁxed using 4% paraformaldehyde
(Sigma-Aldrich) in 1 Dulbecco's phosphate-buffered saline
(DPBS, Life Technologies), permeabilized using 0.2% Triton X-100
(Sigma-Aldrich) in 1 DPBS, and stained for intracellular HIV-1
p24 expression using the anti-p24 antibody, mAB-183, and goat
anti-mouse Alexa-Flour 488. Cellular DNA was stained using
Hoechst 33342 (Life Technologies). Immunostained cells were
imaged using an Image Xpress Micro microscope (Molecular
Devices) and the images analyzed to determine percent infection
and cell number (cell scoring module). To evaluate IFI44 nuclear
translocation, HEK293 cells stably expressing HA-IFI44 were
infected with VSV-G pseudo-typed HIV-NL4-3-GFP virus (ΔEnv),
or mock-treated for 48 h. Fixation and permeabilization were
performed as aforementioned. Cells were stained for IFI44 using
an anti-HA.11 monoclonal rabbit antibody, 16B12, followed by a
Texas Red conjugated goat anti-rabbit secondary antibody. Cellular
DNA was stained with Hoechst 33342. Immunostained cells were
imaged using an Olympus ILL-100 inverted ﬂuorescence micro-
scope. Analyses of the nuclear region of cells were completed
using ImageJ image analysis software (NIH). Hoechst and anti-
IFI44 (Texas Red) images were stacked. The oval tool was used to
create a circular area slightly smaller than each nucleus. The oval
was laid directly on a nucleus, and a pixel measurement was made
for the corresponding anti-HA-IFI44 image. Fifty nuclei were
measured per stack.
Nuclear and cytoplasmic fractionation
HA-IFI44 expressing HEK293 cells were infected with VSV-G
pseudo-typed HIV-NL4-3-GFP virus (ΔEnv) (MOI¼5), or mock
treated for 48 h. Cells were collected, washed with 1 DPBS and
lysed in CE buffer (10 mM HEPES [pH 7.9], 60 mM KCl, 1 mM EDTA,
1 mM DTT, 0.3% NP-40) supplemented with protease inhibitor
tablet (Pierce). Nuclei were pelleted at 4 1C and rinsed once with
CE buffer without NP-40. Nuclei were lysed in NE buffer (20 mM
HEPES [pH 7.9], 420 mM NaCl, 1.5 mM MgCl2, 20% glycerol, adding
0.5 mM PMSF and protease inhibitor tablet freshly) and incubated
at 4 1C for 10 min. Glycerol was added to the CE fraction to 20%.
Cytoplasmic and nuclear fractions were analyzed by SDS-PAGE and
western blot using E-cadherin, JMJD1A, GAPDH, and HA
antibodies.
GST-TAT pull-down
pGEX2TK-TAT1(86R) (NIH AIDS Reagent Repository) or pGEX
empty plasmid was transformed into Escherichia Coli BL21 strain.
Cultures were grown to 0.6–0.8 OD at 37 °C, and induced with
0.1 mM isopropyl-1-thio-galactosidase (IPTG) at 30 1C. Cells were
pelleted, re-suspended in 10 ml ice-cold E. Coli lysis buffer (50 mM
Tris–HCl [pH 8.0], 100 mM NaCl, 0.5 mM EDTA, 5 mM MgCl2, and
freshly added 0.2% NP-40, 2 mM DTT, 0.2 mM PMSF, 200 mg/ml
lysozyme, protease inhibitor tablet), and incubated on ice for 1 h.
Lysate was sonicated brieﬂy and cellular debris was pelleted. Pre-
washed glutathione beads (Promega) were incubated with the
supernatant at 4 1C for 2 h with rotation. Beads were washed three
times each with wash buffer I (50 mM Tris–HCl [pH 7.5], 500 mM
NaCl, 1 mM EGTA, 10% glycerol, 0.1% Triton X-100, and freshly
added 0.1% beta-mercaptoethanol and 1 mM PMSF) and wash
buffer II (50 mM HEPES [ pH 7.5], 100 mM NaCl, 1 mM EGTA, 10%
glycerol, and freshly added 0.1% BME, 1 mM PMSF). 10 μl GST or
GST-TAT beads were eluted in LDS sample buffer (Thermo Scien-
tiﬁc) and analyzed by SDS-PAGE and coomassie blue staining (Bio-
rad). Conﬂuent HEK293 cells stably expressing HA-IFI44 in a 10 cm
plate were harvested and lysed in 1 ml RIPA buffer (50 mM Tris–
HCl [pH 7.4], 150 mM NaCl, 1% NP-40, 0.25% Na deoxycholate,
1 mM EDTA, and freshly added protease inhibitor tablet), and
incubated for 10 min on ice. Lysate was sonicated brieﬂy and
cellular debris was pelleted. To pre-clear the lysate, empty glu-
tathione beads were added for incubation with rotation at 4 1C.
Beads were magnetically removed and the pre-cleared lysate was
then incubated with GST or GST-TAT beads overnight at 4 1C with
rotation. The beads were washed four times with 1 RIPA buffer.
Precipitated protein samples were eluted to 1 LDS sample buffer
and analyzed by SDS-PAGE and western blot using an HA antibody.
Protein co-immunoprecipitation (co-IP)
HEK293 cells stably expressing HA-IFI44 were transfected with
pcDNA-FLAG-TAT plasmid on a 10 cm plate. As a positive control,
pcDNA-FLAG-TAT was co-transfected with a pcDNA-V5-HDAC1
plasmid to 293T cells. 48 h post-transfection, cells were harvested
and lysed in 1 ml RIPA buffer. Cell lysate was sonicated brieﬂy,
cellular debris was pelleted and the supernatant was aspirated to a
new tube. A small aliquot was taken to run as input. To pre-clear,
40 ml protein A/G beads were added to the lysate for incubation for
2 h at 4 1C. The beads were magnetically removed, the lysate was
split equally and 2 mg of mouse HA (for IFI44, V5 for HDAC1), or
IgG control antibody was added for overnight rotation at 4 1C.
20 ml of protein A/G beads was added to each sample for incuba-
tion with rotation for 2 h. The beads were washed for 3 times with
1 RIPA buffer and precipitated protein samples were eluted to
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1 LDS sample buffer and analyzed by SDS-PAGE and western
blot using a rabbit anti-FLAG antibody (Sigma).
Flow cytometry
J-LAT A2, 6.3, or 9.2 cells stably expressing shRNA were induced
with 1 mg/ml prostratin (Sigma-Aldrich) or DMSO as a negative
control. 24 h post-induction, GFP positive cells were sorted using a
FACSCalibur ﬂow cytometer (Becton Dickinson). Results were
analyzed for GFP-expressing cells using FlowJo software
(v10.0.7). Jurkat T cells stably expressing shRNA were infected
with VSV-G pseudo-typed HIV-1 NL4-3-GFP virus (ΔEnv) for 48 h
and then subjected to ﬂow cytometry assay. JLTRG cells (from the
NIH AIDS reagent repository) stably expressing HA-IFI44 or empty
vector were transduced with pcDNA-FLAG-TAT. 48 h post-trans-
duction, cells were sorted. For AGS/BX cells stably expressing HA-
IFI44 or empty vector, EBV lytic replication was induced with
combined treatment of 12-o-tetradecanoyl phorbol-13-acetate
(TPA, 100 nM, Promega) and sodium butyrate (SB, 3 mM, Fisher
Scientiﬁc) for 24 h and subjected to ﬂow cytometry.
Quantitative real-time PCR
SYBR Green primers were used to measure the mRNA level of
the following genes. IFI44 forward, 50- CCA CCG AGA TGT CAG AAA
GAG -30; IFI44 reverse, 50- TGG TAC ATG TGG CTT TGC TC -30.
GAPDH forward, 50- GCC TCT TGT CTC TTA GAT TTG GTC -30;
GAPDH reverse, 50- TAG CAC TCA CCA TGT AGT TGA GGT -30. Total
mRNA extracted from cells (1 mg) was reverse-transcribed using
random hexamers (0.1 mM) and SuperScript III Reverse Transcrip-
tase following the manufacturer's instruction (Life Technologies).
The reverse-transcribed cDNA template was mixed with the
primers (0.1 mM each) and 2 Platinum SYBR Green qPCR Super-
Mix (Life Technologies), which was subjected to real-time PCR
analysis on a 7500 Fast PCR-System (Applied Biosystems). The
following thermal cycles were used: 95 1C, 1 min/95 1C, 5 s; 60 1C,
30 s; 40 cycles.
Luciferase assay
HEK293 cells stably expressing HA-IFI44 or empty vector were
transfected with a pcDNA-FLAG-TAT vector, a HIV-1 LTR luciferase
reporter construct (NIH AIDS Reagent Repository), along with pRL-
TK (Promega) as an internal transfection control. Cells were
processed using the Dual-Glo Luciferase Assay System (Promega).
Plates were read using a Luminoskan Ascent Microplate Lumin-
ometer (Thermo Fisher Scientiﬁc). Relative light units (RLU) were
measured by normalizing the signal from ﬁreﬂy luciferase with
that from Renilla luciferase.
Chromatin immunoprecipitation (ChIP) assay
ChIP assay followed a protocol previously described (Jadlowsky et
al., 2014) with minor changes. HEK293 cells expressing HA-IFI44 were
transduced with pseudo-typed HIV-1 NL4-3-GFP (ΔEnv). 48 h post-
infection, paraformaldehyde (Fisher Scientiﬁc) was added to the
culture media to 0.5% for incubation at room temperature. To stop
the cross-linking reaction, glycine (Fisher Scientiﬁc) was added
(125 mM ﬁnal concentration). Cells were washed twice in ice-cold
PBS and re-suspended in CE buffer at a concentration of 107 cells/ml.
Nuclei were pelleted and re-suspended in SDS lysis buffer (50 mM
Tris–HCl [pH 8.1], 1% SDS, 10 mM EDTA, added protease inhibitor
tablet freshly) at a concentration of 5107 cells/ml and sonicated
(model 120 sonic dismembrator, Fisher Scientiﬁc) for 2 min at 50%
output with 1 s pulsing. Sonicated nuclear extract was diluted 1:10 in
ChIP dilution buffer (16.7 mM Tris–HCl [pH 8.1], 0.01% SDS, 1% Triton
X-100, 1.2 mM EDTA, 150 mM NaCl, protease inhibitor tabled added
freshly). An aliquot was saved as input. 5 mg anti-HA or rabbit IgG
(RIgG) control was added to the rest of the diluted nuclear extract and
samples were incubated at 4 1C with rotation overnight. Protein A/G
beads were pre-incubated for 1 h with 0.5 mg/ml BSA (Fisher Scien-
tiﬁc) and 0.125 mg/ml sonicated herring sperm DNA (Promega) in PBS.
50 ml of the pre-incubated beads was added to each sample for
incubation for 2 h at 4 1C with rotation. Beads were magnetically
recovered and washed once in low-salt immune complex wash buffer
(20 mM Tris–HCl [pH 8.1], 0.1% SDS, 1% Triton X-100, 2 mM EDTA,
150 mM NaCl), once in high-salt immune complex wash buffer
(20 mM Tris–HCl [pH 8.1], 0.1% SDS, 1% Triton X-100, 2 mM EDTA,
500 mM NaCl), once in LiCl buffer (10 mM Tris–HCl [pH 8.1], 0.25 M
LiCl, 1% NP-40, 1% Na deoxycholate, 1 mM EDTA), and twice in TE
buffer (10 mM Tris–HCl [pH 8.1], 0.1 mM EDTA). Input, RIgG, and anti-
HA samples were incubated at 65 1C with 20 ml of 5 M NaCl for 6 h
and at 50 1C for 2 h with 1 ml of 20 mg/ml proteinase K (Life
Technologies), 10 ml of 0.5 M EDTA, and 40 ml of 0.5 M Tris–HCl. DNA
samples were extracted using phenol:chloroform (Fisher Scientiﬁc)
and recovered with ethanol precipitation. Pelleted DNA samples were
re-suspended in nuclease-free water and subjected to semi-
quantitative PCR assays using primers recognizing various regions of
HIV-1 LTR promoter (Lusic et al., 2003): Nuc-0 forward, 50- GAA GGG
CTA ATT TGG TCC CA -30; Nuc-0 reverse, 50- GAT GCA GCT CTC GGG
CCA TG -30. L1(PPR) forward, 50- CGAGAG CTG CAT CCG GAG TA -30; L1
(PPR) reverse, 50- AGC TTT ATT GAG GCT TAA GC -30. Nuc-1 forward,
50- AGT AGT GTG TGC CCG TCT GT -30; Nuc-1 reverse, 50- TTG GCG TAC
TCA CCA GTC GC -30. Nuc-2 forward, 50- ATT TTG ACT AGC GGA GGC
TA -30; Nuc-2 reverse, 50- ACA GCC TTC TGA TGT CTC TA -30. DNA
template and primers were mixed with 2x PCR master mix (Thermo
Scientiﬁc). The following thermal cycles were used: 98 1C, 30 s/98 1C,
5 s; 50 1C, 10 s; 72 1C, 15 s/72 1C 1min; 30 cycles. PCR amplicons were
separated on a 2% agarose gel in 1 Lithium Borate buffer (0.8 g/L
lithium hydroxide monohydrate, 3.6 g/L boric acid, pH 8.0) and
analyzed using the Gel Doc XR imaging system (Universal Hood II,
Bio-rad).
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